In conclusion, the anti‐EGFR mAbs (CTX or NTZ) combined with palliative chemotherapy achieved promising antitumor activity with a tolerable toxicity profile as a first‐line treatment for RM‐NPC. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.